Table 2. Clinical trials in progress.
| Phase | Drugs | Targets |
|---|---|---|
| II | Vemurafenib followed ipilimumab | Immunotherapy plus BRAFi |
| II | LGX818 + MEKi/CDK4,6/FGFRi/PI3Ki/METi | Sequential TKi |
| I/II | Pembrolizumab + dabrafenib + trametinib | Anti-PD1 + BRAFi + MEKi |
| I/II | MEDI4736 + dabrafenib+ trametinib | Anti-PDL1 + BRAFi + MEKi |
| I | Dabrafenib ± trametinib + ipilimumab | Anti-CTL4 + BRAFi/MEKi |
| I/II | Vemurafenib + BKM120 | BRAFi + PI3Ki |
| I/II | Dabrafenib + GSK2141795 | BRAFi + AKTi |
| I/II | Vemurafenib + P1446A-05 | BRAFi + CDKi |
| I | Dabrafenib, trametinib, ipilimumab sequent | BRAFi, MEKi, anti-CTL4 |
| I | GDC-0941 + cobimetinib | PI3Ki + MEKi |
| I | BKM120 + MEK162 | PI3Ki + MEKi |